Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer’s disease-Reference-Cited by-同舟云学术

Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer’s disease

Published:2019-11-19 Issue:1 Volume:42 Page:159-167
ISSN:2509-2715
Container-title:GeroScience
language:en
Short-container-title:GeroScience

Author:

Cervellati Carlo^ORCID,Trentini Alessandro,Rosta Valentina,Passaro Angelina,Bosi Cristina,Sanz Juana Maria,Bonazzi Stefania,Pacifico Salvatore,Seripa Davide,Valacchi Giuseppe,Guerini Remo,Zuliani Giovanni

Publisher

Springer Science and Business Media LLC

Subject

Geriatrics and Gerontology,Aging

Link

http://link.springer.com/content/pdf/10.1007/s11357-019-00127-6.pdf

Reference33 articles.

1. Baazaoui N, Iqbal K (2018) A novel therapeutic approach to treat Alzheimer’s disease by neurotrophic support during the period of synaptic compensation. J Alzheimers Dis 62:1211–1218

2. Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, Staufenbiel M, Paganetti P (2002) Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem 80:799–806

3. Bruford E, Lush MJ, Wright MW, Sneddon TP, Povey S, Birney E (2008) The HGNC database in 2008: a resource for the human genome. Nucleic Acids Res 36:D445–D448

4. Butterfield DA, Poon HF, St. Clair D et al (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer’s disease. Neurobiol Dis 22:223–232

5. Cervellati C, Cremonini E, Bosi C, Magon S, Zurlo A, Bergamini CM, Zuliani G (2013) Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer’s disease. Curr Alzheimer Res 10:365–372

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-situ nanozyme catalytic amplification coupled with a universal antibody orientation strategy based electrochemical immunosensor for AD-related biomarker;Biosensors and Bioelectronics;2024-12

2. Review of single-molecule immunoassays: Non-chip and on-chip Assays;Analytica Chimica Acta;2024-09

3. Exploring the therapeutic potential of prolinamides as multi-targeted agents for Alzheimer’s disease treatment: molecular docking and molecular dynamic simulation studies;In Silico Pharmacology;2024-08-31

4. Inhibition of BACE1 affected both its Aβ producing and degrading activities and increased Aβ42 and Aβ40 levels at high-level BACE1 expression;Journal of Biological Chemistry;2024-08

5. Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study;International Journal of Molecular Sciences;2024-07-30